Research graph
References from A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2020 · External reference
A real-time dashboard of clinical trials for COVID-19
10.1016/s2589-7500(20)30086-8 · 2020 · External reference
Unresolved reference
2020 · External reference
COVID-19 antibodies on trial
2020 · External reference
Pathogenesis of COVID-19 from a cell biology perspective
10.1183/13993003.00607-2020 · 2020 · External reference
Global initiative for asthma: global strategy for asthma management and prevention (Updated 2020)
2020 · External reference
Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs
10.1128/aac.00819-20 · 2020 · External reference
SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection
10.1038/s41467-019-13659-4 · 2019 · External reference
Analysis of SARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide as putative antiviral therapeutics
2020 · External reference
Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects
10.1371/journal.ppat.1002976 · 2012 · External reference
Broad spectrum antiviral agent niclosamide and its therapeutic potential
10.1021/acsinfecdis.0c00052 · 2020 · External reference
Broad-spectrum, patient-adaptable inhaled niclosamide-lysozyme particles are efficacious against coronaviruses in lethal murine infection models
2020 · External reference
Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication
10.1016/j.virusres.2020.198277 · 2021 · External reference
Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial
10.1200/jco.2018.36.15_suppl.e14536 · 2018 · External reference
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer
10.1371/journal.pone.0198389 · 2018 · External reference
Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats
2006 · External reference
The biology and toxicology of mollucidides, Bayluscide®
10.1016/0163-7258(82)90064-x · 1983 · External reference
GINA 2019: a fundamental change in asthma management
10.1183/13993003.01046-2019 · 2019 · External reference
SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract
10.1016/j.cell.2020.05.042 · 2020 · External reference
